HRP20240222T1 - Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata - Google Patents
Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata Download PDFInfo
- Publication number
- HRP20240222T1 HRP20240222T1 HRP20240222TT HRP20240222T HRP20240222T1 HR P20240222 T1 HRP20240222 T1 HR P20240222T1 HR P20240222T T HRP20240222T T HR P20240222TT HR P20240222 T HRP20240222 T HR P20240222T HR P20240222 T1 HRP20240222 T1 HR P20240222T1
- Authority
- HR
- Croatia
- Prior art keywords
- detergent
- chromatography
- variants
- original flow
- product
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 33
- 239000003599 detergent Substances 0.000 title claims 25
- 230000002779 inactivation Effects 0.000 title claims 2
- 230000003612 virological effect Effects 0.000 title 1
- 238000004587 chromatography analysis Methods 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 230000008569 process Effects 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 238000001042 affinity chromatography Methods 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 101710120037 Toxin CcdB Proteins 0.000 claims 2
- 239000002518 antifoaming agent Substances 0.000 claims 2
- 239000013019 capto adhere Substances 0.000 claims 2
- 239000012930 cell culture fluid Substances 0.000 claims 2
- 238000004255 ion exchange chromatography Methods 0.000 claims 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000005277 cation exchange chromatography Methods 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000006240 deamidation Effects 0.000 claims 1
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 231100000492 no effect concentration Toxicity 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- 231100000610 predicted environmental concentration Toxicity 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- -1 regulatory factor Proteins 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (26)
1. Postupak inaktivacije virusa u izvornom protoku proizvoda u procesu proizvodnje terapijskog polipeptida, naznačen time, da postupak uključuje korak izlaganja izvornog protoka deterdžentu, pri čemu je deterdžent ekološki kompatibilan, s time, da ekološki kompatibilan deterdžent ima CAS registarski broj CAS 58846-77-8, CAS 59122-55-3, CAS 64366-70-7, CAS 27252-75-1, CAS 132778-08-6, CAS 110615-47-9 ili CAS 68515-73-1.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da je nakon odlaganja očekivana koncentracija deterdženta u okolišu (eng. Predicted Environmental Concentration, PEC) u prihvatnom vodnom tijelu kao rezultat uporabe deterdženta ispod očekivane koncentracije deterdženta bez učinka (engl. Predicted No-Effect Concentration, PNEC).
3. Postupak prema patentnom zahtjevu 1 ili 2, naznačen time, da se postupkom održava kvaliteta proizvoda terapijskog polipeptida u usporedbi s postupkom koji koristi Triton X-100 ili postupkom bez deterdženta.
4. Postupak prema patentnom zahtjevu 3, naznačen time, da kvaliteta proizvoda terapijskog polipeptida dovodi do najviše 5 % promjene u varijantama proizvoda u odnosu na ukupnu količinu polipeptida u izvornom protoku proizvoda.
5. Postupak prema patentnom zahtjevu 4, naznačen time, da varijante proizvoda
a) ne povećavaju se za više od 5% od ukupne količine polipeptida u izvornom protoku proizvoda; i/ili
b) su varijante veličine, varijante naboja, varijante oksidacije, varijante deamidacije, varijante glikacije ili varijante s promijenjenim glikanskim profilima; i/ili
c) varijante su kisele i/ili bazične varijante proizvoda.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da izlaganje izvornog protoka deterdžentu ne
a) povećava fragmentaciju polipeptida za više od oko 5%; i/ili
b) povećava agregaciju u izvornom protoku za više od oko 5%; i/ili
c) smanjuje prinos polipeptida u procesu proizvodnje za više od oko 5%.
7. Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se deterdžent dodaje u izvorni protok do postizanja konačne koncentracije od
a) oko 0,01% do oko 10%; i/ili
b) oko 0,3% do oko 1%.
8. Postupak prema bilo kojem od patentnih zahtjeva od 1do 7, naznačen time, da se izvorni protok izlaže deterdžentu
a) najmanje oko 1 minute do najmanje oko 48 sati, i/ili
b) najmanje oko 15 minuta do najmanje oko 3 sata; i/ili
c) najmanje oko 1 sat; i/ili
d) na otprilike 4 °C do otprilike 30 °C; i/ili
e) na otprilike 15 °C do otprilike 20 °C.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da deterdžent
a) je neionski deterdžent ili cviterionski deterdžent; i/ili
b) ima hidrofilno-lipofilni balans (HLB) od oko 12 do oko 15; i/ili
c) ne sadrži niti formira oktilfenol; i/ili
d) ne sadrži niti formira peroksid.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da
a) izvorni protok sadrži deterdžent koji je niske zamućenosti; i/ili
b) dodavanje deterdženta u izvorni protok ne povećava zamućenost izvornog protoka.
11. Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da deterdžent sadrži
a) jedan ili više surfaktanata; i/ili
b) jedan ili više surfaktanata, konzervansa, i kelatnih sredstava.
12. Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da izvorni protok sadrži
a) fluid sakupljene stanične kulture, pri čemu se po mogućnosti deterdžent dodaje fluidu sakupljene stanične kulture; i/ili
b) skup uzetih uzoraka ili skup dobivenog proizvoda.
13. Postupak prema patentnom zahtjevu 12, naznačen time, da skup uzetih uzoraka ili skup dobivenog proizvoda predstavlja
a) skup afinitetne kromatografije; i/ili
b) skup proteina A, skup proteina G ili skup proteina L.
14. Postupak prema patentnom zahtjevu 12, naznačen time, da skup uzetih uzoraka ili skup dobivenog proizvoda predstavlja
a) skup kombinirane kromatografije; i/ili
b) CaptoAdhere skup.
15. Postupak prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da se deterdžent koristi u kombinaciji sa sredstvom protiv pjenjenja, pri čemu je po mogućnosti sredstvo protiv pjenjenja simetikon.
16. Postupak prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da je virus
a) virus s ovojnicom; i/ili
b) retrovirus, herpesvirus, flavivirus, poksvirus, hepadnavirus, virus hepatitisa, ortomiksovirus, paramiksovirus, rabdovirus ili togavirus.
17. Postupak prema bilo kojem od patentnih zahtjeva 1 do 16, naznačen time, da je vrijednost logaritamske redukcije virusa (engl. log reduction value, LRV) deterdženta u izvornom protoku
a) veća od otprilike jedan; i/ili
b) veća od otprilike četiri.
18. Postupak prema patentnom zahtjevu 17, naznačen time, da se LRV izračunava na temelju testa infektivnosti, pri čemu je po mogućnosti test infektivnosti test plakova ili test TCID50.
19. Postupak prema bilo kojem od patentnih zahtjeva 1 do 18, naznačen time, da Postupak nadalje uključuje korak filtriranja izvornog protoka nakon dodavanja deterdženta.
20. Postupak prema patentnom zahtjevu 19, naznačen time, da je izvorni protok filtriran
a) najmanje oko 15 minuta do najmanje oko 48 sati nakon dodavanja deterdženta; i/ili
b) najmanje oko 1 sat do najmanje oko 3 sata nakon dodavanja deterdženta; i/ili
c) otprilike 1 sat nakon dodavanja deterdženta.
21. Postupak prema patentnom zahtjevu 19 ili 20, naznačen time, da filter je ultrafilter ili dubinski filter.
22. Postupak prema bilo kojem od patentnih zahtjeva 1 do 21, naznačen time, da se izvorni protok podvrgava kromatografiji nakon dodavanja deterdženta.
23. Postupak prema patentnom zahtjevu 22, naznačen time, da je kromatografija jedna ili više od afinitetne kromatografije, kromatografije ionske izmjene, kromatografije hidrofobnih interakcija, kromatografije hidroksiapatita ili kombinirane kromatografije.
24. Postupak prema patentnom zahtjevu 23, naznačen time, da
a) afinitetna kromatografija je kromatografija proteina A, kromatografija proteina G ili kromatografija proteina L; ili
b) kromatografija ionske izmjene je kromatografija anionske izmjene ili kromatografija kationske izmjene; ili
c) kombinirana kromatografija je CaptoAdhere kromatografija.
25. Postupak prema bilo kojem od patentnih zahtjeva 1 do 24, naznačen time, da terapijski polipeptid
a) predstavlja protutijelo, imunoadhezin, enzim, faktor rasta, receptor, hormon, regulatorni faktor, citokin, Fc fuzijski polipeptid, antigen ili vezivno sredstvo; i/ili
b) proizveden je u stanicama sisavaca, pri čemu je po mogućnosti stanična linija sisavaca stanica jajnika kineskog hrčka (CHO) ili stanica bubrega mladunčeta hrčka (BHK), stanica mišjeg hibridoma ili stanica mišjeg mijeloma.
26. Postupak prema patentnom zahtjevu 25, naznačen time, da je protutijelo monoklonsko protutijelo, kimerno protutijelo, humanizirano protutijelo, ljudsko protutijelo, bispecifično protutijelo ili fragment protutijela.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361905075P | 2013-11-15 | 2013-11-15 | |
| US201461937284P | 2014-02-07 | 2014-02-07 | |
| PCT/US2014/065391 WO2015073633A1 (en) | 2013-11-15 | 2014-11-13 | Methods for viral inactivation using eco-friendly detergents |
| EP14862284.8A EP3068417B1 (en) | 2013-11-15 | 2014-11-13 | Methods for viral inactivation using eco-friendly detergents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240222T1 true HRP20240222T1 (hr) | 2024-04-26 |
Family
ID=53057993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240222TT HRP20240222T1 (hr) | 2013-11-15 | 2014-11-13 | Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10611795B2 (hr) |
| EP (1) | EP3068417B1 (hr) |
| JP (3) | JP6993083B2 (hr) |
| KR (1) | KR102238133B1 (hr) |
| CN (2) | CN105722523B (hr) |
| CA (1) | CA2930687C (hr) |
| HK (1) | HK1225990A1 (hr) |
| HR (1) | HRP20240222T1 (hr) |
| MX (1) | MX2016006167A (hr) |
| PL (1) | PL3068417T3 (hr) |
| RU (1) | RU2707951C1 (hr) |
| WO (1) | WO2015073633A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108333261A (zh) * | 2017-01-20 | 2018-07-27 | 湖北生物医药产业技术研究院有限公司 | 检测蛋白电荷变异体的方法及确定生物制品生产工艺的方法 |
| CN109022377A (zh) * | 2017-06-12 | 2018-12-18 | 舒泰神（北京）生物制药股份有限公司 | 一种杆状病毒表达系统中杆状病毒的灭活方法 |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| MX2020002939A (es) | 2017-09-18 | 2020-07-22 | Bayer Healthcare Llc | Metodos de inactivacion de virus utilizando n-metilglutamida y sus derivados. |
| CN111511756B (zh) * | 2017-12-19 | 2023-11-03 | 康诺贝林伦瑙有限公司 | 使用烷基糖苷类进行蛋白质纯化和病毒灭活 |
| KR102270048B1 (ko) | 2020-07-10 | 2021-06-28 | 주식회사 녹십자 | 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법 |
| US20220106539A1 (en) | 2018-09-28 | 2022-04-07 | Siemens Healthcare Diagnostics Inc. | Wash reagent containing alkoxylated fatty alcohol and methods of production and use thereof |
| SG11202103790WA (en) * | 2018-11-15 | 2021-05-28 | Bayer Healthcare Llc | Viral inactivation methods for continuous manufacturing of antibodies |
| US20220106573A1 (en) | 2019-03-19 | 2022-04-07 | Amgen Inc. | Alternate detergents for viral inactivation |
| CN115066266A (zh) * | 2019-12-12 | 2022-09-16 | 伊莱利利公司 | 用环保洗涤剂灭活病毒的方法 |
| CN111318264B (zh) * | 2020-02-15 | 2021-11-23 | 江苏大学 | 一种硼亲和分子印迹搅拌棒的制备方法及应用于邻苯二酚的吸附分离 |
| US20230374575A1 (en) | 2020-10-06 | 2023-11-23 | Qiagen Gmbh | Method for virus detection |
| WO2022175429A1 (en) | 2021-02-19 | 2022-08-25 | Qiagen Gmbh | Method for virus detection |
| WO2023020914A1 (en) * | 2021-08-18 | 2023-02-23 | Biotest Ag | Dry heat treatment of plasma-derived factor viii |
| WO2023115027A2 (en) | 2021-12-16 | 2023-06-22 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US4939176A (en) * | 1988-12-20 | 1990-07-03 | Miles Inc. | Viral inactivation process |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH05503003A (ja) | 1989-11-22 | 1993-05-27 | ジェネンテク，インコーポレイテッド | 潜在性関与ペプチドおよびその使用 |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
| HRP940645A2 (en) * | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
| US6610316B2 (en) * | 1997-05-30 | 2003-08-26 | Shanbrom Technologies, Llc | Disinfection by particle-bound and insolubilized detergents |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US20030228244A1 (en) | 2002-06-05 | 2003-12-11 | Perez Libardo A. | Inhibition of the depletion of metal values from pregnant lixiviant solutions |
| WO2005014777A2 (en) * | 2002-10-16 | 2005-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| JP4874806B2 (ja) * | 2003-12-01 | 2012-02-15 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 液体因子ｖｉｉ組成物のウイルス濾過 |
| WO2007002465A2 (en) * | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| CN101479295A (zh) * | 2006-05-04 | 2009-07-08 | 健泰科生物技术公司 | 涉及zpa多肽的方法和组合物 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US7838485B2 (en) | 2007-03-08 | 2010-11-23 | American Sterilizer Company | Biodegradable alkaline disinfectant cleaner with analyzable surfactant |
| US8871807B2 (en) * | 2008-03-28 | 2014-10-28 | Ecolab Usa Inc. | Detergents capable of cleaning, bleaching, sanitizing and/or disinfecting textiles including sulfoperoxycarboxylic acids |
| TWI445714B (zh) * | 2009-05-27 | 2014-07-21 | Baxter Int | 產製用於皮下使用之高濃度免疫球蛋白製備物之方法 |
| KR101778317B1 (ko) * | 2009-08-13 | 2017-09-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법 |
| WO2011028753A1 (en) * | 2009-09-01 | 2011-03-10 | Genentech, Inc. | Enhanced protein purification through a modified protein a elution |
| WO2012036700A1 (en) * | 2010-09-17 | 2012-03-22 | Ecolab Usa Inc. | Laundry composition for treatment of sunscreen stains based on extended chain surfactants |
| US8580727B2 (en) * | 2010-09-17 | 2013-11-12 | Ecolab Usa Inc. | Reduced caustic laundry detergents based on extended chain surfactants |
| EP2640816A1 (en) * | 2010-11-16 | 2013-09-25 | Dow Global Technologies LLC | Hard surface cleaners comprising low voc, low odor alkanolamines |
| KR101854310B1 (ko) * | 2010-12-15 | 2018-05-04 | 박스알타 인코퍼레이티드 | 개선된 용매-세제법을 이용한 바이러스 불활성화 |
| TR201810703T4 (tr) | 2011-03-25 | 2018-08-27 | Hoffmann La Roche | Yeni protein saflaştırma yöntemleri. |
-
2014
- 2014-11-13 CA CA2930687A patent/CA2930687C/en active Active
- 2014-11-13 CN CN201480061631.2A patent/CN105722523B/zh active Active
- 2014-11-13 EP EP14862284.8A patent/EP3068417B1/en active Active
- 2014-11-13 CN CN202210637641.2A patent/CN115177759A/zh active Pending
- 2014-11-13 KR KR1020167015475A patent/KR102238133B1/ko active IP Right Grant
- 2014-11-13 PL PL14862284.8T patent/PL3068417T3/pl unknown
- 2014-11-13 HR HRP20240222TT patent/HRP20240222T1/hr unknown
- 2014-11-13 WO PCT/US2014/065391 patent/WO2015073633A1/en active Application Filing
- 2014-11-13 JP JP2016530926A patent/JP6993083B2/ja active Active
- 2014-11-13 MX MX2016006167A patent/MX2016006167A/es unknown
- 2014-11-13 RU RU2016123375A patent/RU2707951C1/ru active
-
2016
- 2016-05-13 US US15/154,235 patent/US10611795B2/en active Active
- 2016-12-20 HK HK16114478A patent/HK1225990A1/zh unknown
-
2019
- 2019-11-18 JP JP2019208228A patent/JP2020063253A/ja not_active Withdrawn
-
2021
- 2021-11-04 JP JP2021180047A patent/JP2022036940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3068417A1 (en) | 2016-09-21 |
| WO2015073633A1 (en) | 2015-05-21 |
| JP2020063253A (ja) | 2020-04-23 |
| CA2930687C (en) | 2024-04-23 |
| KR20160085321A (ko) | 2016-07-15 |
| CN105722523B (zh) | 2022-06-14 |
| CA2930687A1 (en) | 2015-05-21 |
| EP3068417C0 (en) | 2023-12-27 |
| CN115177759A (zh) | 2022-10-14 |
| CN105722523A (zh) | 2016-06-29 |
| US10611795B2 (en) | 2020-04-07 |
| JP2022036940A (ja) | 2022-03-08 |
| JP6993083B2 (ja) | 2022-02-04 |
| PL3068417T3 (pl) | 2024-05-13 |
| JP2017501974A (ja) | 2017-01-19 |
| KR102238133B1 (ko) | 2021-04-09 |
| RU2707951C1 (ru) | 2019-12-02 |
| EP3068417B1 (en) | 2023-12-27 |
| EP3068417A4 (en) | 2017-07-05 |
| US20160333046A1 (en) | 2016-11-17 |
| HK1225990A1 (zh) | 2017-09-22 |
| MX2016006167A (es) | 2016-08-08 |
| RU2016123375A (ru) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240222T1 (hr) | Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata | |
| RU2013120948A (ru) | Способ очистки белков | |
| ES2784749T3 (es) | Purificación de inmunoglobulina con el uso de etapas de limpieza previa | |
| JP6783767B2 (ja) | 組換えタンパク質を精製する方法 | |
| HRP20201118T1 (hr) | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije | |
| RU2603347C2 (ru) | Очистка белка с использованием бис-трис буфера | |
| CA2911462C (en) | Continuous multistep process for purifying antibodies | |
| HRP20200565T1 (hr) | Cd47 ciljane terapije za liječenje infektivne bolesti | |
| US10634589B2 (en) | Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light | |
| RU2012154652A (ru) | Устройство для очистки белка и способ применения указанного устройства | |
| EA201992487A1 (ru) | Способы очистки рекомбинантного adamts13 и других белков и их композиции | |
| BRPI0911699B8 (pt) | vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste | |
| JP2012528190A (ja) | 皮下使用の高濃度免疫グロブリン製剤を生成する方法 | |
| AR053633A1 (es) | Metodos para purificar proteinas que contienen una region fc | |
| RU2014101484A (ru) | Способ получения вирусного антигена и вакцин | |
| JP2022520793A (ja) | 自動バイオ製造システム、施設、及びプロセス | |
| CN103608352A (zh) | 蛋白制剂的制造方法 | |
| RU2019109975A (ru) | Способы очистки антител | |
| HRP20230667T1 (hr) | Postupci povecanja sadrzaja manoze u rekombinantnim proteinima | |
| HRP20200710T1 (hr) | Novi postupak za efikasno pročišćavanje humanog serumskog albumina | |
| KR20210118815A (ko) | 활성탄 재료를 사용하는 공정을 포함하는 항체 정제 방법 | |
| Kuczynski et al. | Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS‐CoV‐2 | |
| Barnette et al. | Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process | |
| WO2024058110A1 (ja) | 抗体の精製方法 | |
| EA044919B1 (ru) | Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения |